Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ferric carboxymaltose
- Development stage
- Approved
- Lead developer
- Vifor Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ferric carboxymaltose is an iron replacement product used to treat iron deficiency anemia (IDA). It's administered intravenously, delivering iron directly into the bloodstream, which allows 100% of the iron to be delivered without going through the digestive system. The drug is designed to slowly release iron once inside the body, which may decrease potential side effects. Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.
- Brand names
- InjectaferFerinject
- Other names
- ferric carboxy-maltoseFCM
Beyond the preview
Go deeper on ferric carboxymaltose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ferric carboxymaltose.